Apremilast EP Impurity F
✓
데이터 정확도 100%
연중무휴 과학적 지원
⬡
제품 품질에 대한 무관용 원칙

재고 위치

  • New Jersey, USA
  • Czech Republic, EU
  • Mumbai, India

* 재고 가용성에 따라 다름

Documentation

MSDS 다운로드

샘플 COA 다운로드

포함 사항: HPLC, MASS/LC-MS, 1H NMR, FT-IR, 함량, 구조 규명 보고서(SER), 그리고 제품에 따라 추가 분석 데이터가 제공됩니다.

2731075-81-1Apremilast EP Impurity F

● 재고 있음

카탈로그 번호:VL6770006
CAS 번호:2731075-81-1
분자식:C20H24N2O7S
분자량:436.48 g/mol

에 대한 추가 정보 CAS 2731075-81-1

모약물

Apremilast

IUPAC명

2-amino-6-((1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)carbamoyl)benzoic acid

약전 동의어

N/A

Other Synonyms

rac-N-Deacetyl-2-carboxy-(seco-phthalimido) Apremilast

Smile

O=C(O)C1=C(C(NC(C2=CC=C(OC)C(OCC)=C2)CS(=O)(C)=O)=O)C=CC=C1N

Inchl

InChI=1S/C20H24N2O7S/c1-4-29-17-10-12(8-9-16(17)28-2)15(11-30(3,26)27)22-19(23)13-6-5-7-14(21)18(13)20(24)25/h5-10,15H,4,11,21H2,1-3H3,(H,22,23)(H,24,25)

설명

Apremilast EP Impurity F is a meticulously characterized reference material that complies with rigorous regulatory requirements, including those defined by USP, EMA, JP, and BP. This product plays a crucial role in Abbreviated New Drug Applications (ANDA), New Drug Applications (NDA), and the commercial manufacturing of Apremilast. It is further supported by a detailed Structure Elucidation Report (SER), ensuring high accuracy and reliability across a broad range of analytical applications. Apremilast EP Impurity F is an oral phosphodiesterase 4 inhibitor that has an impact on a wide range of inflammatory mediators involved in psoriasis and psoriatic arthritis, this is a novel treatment that focuses on maintaining a balance between pro-inflammatory and anti-inflammatory signals.

References

Schafer, Peter. “Apremilast Mechanism of Action and Application to Psoriasis and Psoriatic Arthritis.” Biochemical Pharmacology, vol. 83, no. 12, June 2012, pp. 1583–90, https://doi.org/10.1016/j.bcp.2012.01.001.

견적 요청

"*" indicates required fields

This field is for validation purposes and should be left unchanged.
Products quotation
Name
Url